Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Amortization of Deferred Charges (2022 - 2025)

BioXcel Therapeutics (BTAI) has 4 years of Amortization of Deferred Charges data on record, last reported at $440000.0 in Q3 2025.

  • For Q3 2025, Amortization of Deferred Charges rose 315.09% year-over-year to $440000.0; the TTM value through Sep 2025 reached $7.5 million, up 611.8%, while the annual FY2024 figure was $6.5 million, 249.52% up from the prior year.
  • Amortization of Deferred Charges reached $440000.0 in Q3 2025 per BTAI's latest filing, up from -$1.9 million in the prior quarter.
  • Across five years, Amortization of Deferred Charges topped out at $6.3 million in Q4 2024 and bottomed at -$1.9 million in Q2 2025.
  • Average Amortization of Deferred Charges over 4 years is $798153.8, with a median of $356000.0 recorded in 2023.
  • The widest YoY moves for Amortization of Deferred Charges: up 6104.65% in 2025, down 2105.21% in 2025.
  • A 4-year view of Amortization of Deferred Charges shows it stood at $457000.0 in 2022, then skyrocketed by 76.37% to $806000.0 in 2023, then surged by 681.39% to $6.3 million in 2024, then plummeted by 93.01% to $440000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Amortization of Deferred Charges were $440000.0 in Q3 2025, -$1.9 million in Q2 2025, and $2.7 million in Q1 2025.